文献速递临床试验与 GCP基础与转化研究

无乳糖低紫水化合物配方用于住院严重急性营养不良儿童稳定期的双盲随机对照试验

A reduced-carbohydrate and lactose-free formulation for stabilization among hospitalized children with severe acute malnutrition: A double-blind, randomized controlled trial.
PubMed 文献 · PLoS Med · 2019-02-26

结果显示两组中位稳定时间均为3天(IQR 2-5天),组间差异无统计学意义(0.23天,95%CI -0.13至0.60,P=0.59),住院死亡率、腹泻累积天数等次要结局亦无差异。结论认为无乳糖低紫水化合物配方未能改善临床结局,生化分析提示该配方可能仍超过肠道吸收的紫水化合物负荷阈值。

要点

  • 无乳糖低紫水化合物F75配方未缩短住院SAM儿童稳定时间(中位3天,P=0.59)。
  • 生化分析提示无乳糖配方可能仍超过肠道吸收的紫水化合物负荷阈值。

核心结论

  • 对住院医学复杂型SAM儿童在稳定期经验性使用无乳糖、低紫水化合物配方未能改善临床结局。

研究设计与样本

  • 主要终点为WHO定义的稳定时间,采用意向性治疗分析;次要终点包括住院死亡率、腹泻及吸收不良和再喂养综合征的生化指标。

主要发现

  • 中位稳定时间为3天(IQR 2-5天),两组间相似(0.23天,95%CI -0.13至0.60,P=0.59)。
  • 未发现入院腹泻、年龄、水肿或HIV状态对干预效果有修饰作用。
  • 腹泻累积天数(P=0.27)、肠内补液(P=0.42)或静脉补液(P=0.19)天数、稳定前其他严重不良事件及第3天血清和粪便生化指标两组间均无差异。

关键数值与推荐

  • 主要终点稳定时间按WHO指南定义,包括急性疾病恢复的临床证据及食欲恢复所体现的代谢稳定。

临床怎么用

  • 对于住院医学复杂型SAM儿童,稳定期使用无乳糖低紫水化合物配方未显示优于标准F75配方。
  • 生化分析提示无乳糖配方可能仍超过肠道吸收的紫水化合物负荷阈值,可能限制其在复杂型SAM中的 usefulness。

局限性

  • 主要结局临床稳定基于WHO指南,包含临床恢复证据及食欲恢复所体现的代谢稳定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Children with medically complicated severe acute malnutrition (SAM) have high risk of inpatient mortality. Diarrhea, carbohydrate malabsorption, and refeeding syndrome may contribute to early mortality and delayed recovery. We tested the hypothesis that a lactose-free, low-carbohydrate F75 milk would serve to limit these risks, thereby reducing the number of days in the stabilization phase. METHODS AND FINDINGS: In a multicenter double-blind trial, hospitalized severely malnourished children were randomized to receive standard formula (F75) or isocaloric modified F75 (mF75) without lactose and with reduced carbohydrate. The primary endpoint was time to stabilization, as defined by the World Health Organization (WHO), with intention-to-treat analysis. Secondary outcomes included in-hospital mortality, diarrhea, and biochemical features of malabsorption and refeeding syndrome. The trial was registered at clinicaltrials.gov (NCT02246296). Four hundred eighteen and 425 severely malnourished children were randomized to F75 and mF75, respectively, with 516 (61%) enrolled in Kenya and 327 (39%) in Malawi. Children with a median age of 16 months were enrolled between 4 December 2014 and 24 December 2015. One hundred ninety-four (46%) children assigned to F75 and 188 (44%) to mF75 had diarrhea at admission. Median time to stabilization was 3 days (IQR 2-5 days), which was similar between randomized groups (0.23 [95% CI -0.13 to 0.60], P = 0.59). There was no evidence of effect modification by diarrhea at admission, age, edema, or HIV status. Thirty-six and 39 children died before stabilization in the F75 and in mF75 arm, respectively (P = 0.84). Cumulative days with diarrhea (P = 0.27), enteral (P = 0.42) or intravenous fluids (P = 0.19), other serious adverse events before stabilization, and serum and stool biochemistry at day 3 did not differ between groups. The main limitation was that the primary outcome of clinical stabilization was based on WHO guidelines, comprising clinical evidence of recovery from acute illness as well as metabolic stabilization evidenced by recovery of appetite. CONCLUSIONS: Empirically treating hospitalized severely malnourished children during the stabilization phase with lactose-free, reduced-carbohydrate milk formula did not improve clinical outcomes. The biochemical analyses suggest that the lactose-free formulae may still exceed a carbohydrate load threshold for intestinal absorption, which may limit their usefulness in the context of complicated SAM. TRIAL REGISTRATION: ClinicalTrials.gov NCT02246296.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Bandsma RHJ, Voskuijl W, Chimwezi E, et al. A reduced-carbohydrate and lactose-free formulation for stabilization among hospitalized children with severe acute malnutrition: A double-blind, randomized controlled trial. PLoS Med. 2019. PMID: 30807589. doi:10.1371/journal.pmed.1002747

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。